Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, Agema WR, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. Thromb Haemost. 2005 Mar;93(3):564-9. doi: 10.1160/TH04-11-0708. Thromb Haemost. 2005. PMID: 15735811 Clinical Trial.
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV. de Groot E, et al. Among authors: jukema jw. Am J Cardiol. 1995 Sep 28;76(9):40C-46C. doi: 10.1016/s0002-9149(99)80469-x. Am J Cardiol. 1995. PMID: 7572685 Clinical Trial.
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al. Jukema JW, et al. Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528. Circulation. 1995. PMID: 7743614 Clinical Trial.
Progression and regression of coronary atherosclerosis.
Bruschke AV, Jukema JW, Van der Wall EE. Bruschke AV, et al. Among authors: jukema jw. Indian Heart J. 1993 Jul-Aug;45(4):259-64. Indian Heart J. 1993. PMID: 8138275 Review. No abstract available.
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV. Jukema JW, et al. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):425-30. doi: 10.1161/01.atv.16.3.425. Arterioscler Thromb Vasc Biol. 1996. PMID: 8630669 Clinical Trial.
Micro stent, quantitative coronary angiography, and procedural results.
Tresukosol D, Schalij MJ, Savalle LH, Jukema JW, Buis B, Reiber JH, Bruschke AV. Tresukosol D, et al. Among authors: jukema jw. Cathet Cardiovasc Diagn. 1996 Jun;38(2):135-43. doi: 10.1002/(SICI)1097-0304(199606)38:2<135::AID-CCD4>3.0.CO;2-A. Cathet Cardiovasc Diagn. 1996. PMID: 8776514
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
1,130 results